ACTG A5209 EZETIMIBE (ZETIA) IN COMBINATION WITH STATIN THERAPY FOR THE TREATMEN

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 A5209是一项双盲、随机、安慰剂对照的交叉研究，旨在确定依折麦布(Zetia)治疗与正在进行的他汀类药物联合治疗低密度脂蛋白升高的艾滋病毒感染者的安全性、有效性和耐受性。主要目的是评估在HAART和他汀类药物治疗的稳定背景中加入Ezetimibe 12周后直接测量的低密度脂蛋白-c的变化与服用安慰剂12周后的低密度脂蛋白的变化，并评估在HAART和他汀类药物治疗的稳定背景中加入Ezetimibe的安全性和耐受性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A5209 is a double-blind, randomized, placebo-controlled, crossover study designed to determine the safety, efficacy, and tolerability of ezetimibe (Zetia) therapy in combination with ongoing statin therapy in HIV-infected subjects with elevated LDL cholesterol. The primary objectives are to evaluate the change in directly measured LDL-c after the addition of Ezetimibe to a stable background of HAART and statin therapy for 12 weeks compared with the change in LDL-c after 12 weeks of placebo, and to evaluate the safety and tolerability of ezetimibe added to a stable background of HAART and statin therapy.